Ó£»¨ÊÓƵ

Skip to main content

TableÌý3 Predictors of hesitancy regardingÌýtheÌýsecond booster dose of COVID-19 vaccine among the general population in China (n = 10,164)

From: Uptake and hesitancy of the second booster dose of COVID-19 vaccine among the general population in China after the surge period of the COVID-19 pandemic: a large-scale national study

Variables

Univariate analysis

Multivariate analysis

cOR (95%CI)

P

aOR(95%CI)

P

Gender

 M²¹±ô±ð

REF

Ìý

REF

Ìý

 F±ð³¾²¹±ô±ð

1.07 (0.98–1.17)

0.111

1.22 (1.10–1.28)

 &±ô³Ù; 0.001

Age

 18–59

REF

Ìý

REF

Ìý

 60 and above

0.62 (0.47–0.80)

 &±ô³Ù; 0.001

0.56 (0.41–0.76)

 &±ô³Ù; 0.001

Region

 C±ð²Ô³Ù°ù²¹±ô

REF

Ìý

REF

Ìý

 N´Ç°ù³Ù³ó

0.84 (0.75–0.95)

0.004

0.95 (0.84–1.08)

0.419

 E²¹²õ³Ù

0.95 (0.76–1.19)

0.667

0.96 (0.76–1.22)

0.740

â€Çȴdzܳٳó

0.75 (0.64–0.86)

 &±ô³Ù; 0.001

0.77 (0.66–0.90)

0.001

 W±ð²õ³Ù

1.05 (0.93–1.19)

0.41

0.98 (0.86–1.12)

0.783

Education level

 Primary school and below

REF

Ìý

REF

Ìý

 Junior high school

1.19 (0.76–1.85)

0.451

0.97 (0.61–1.61)

0.992

 Senior high school

1.40 (0.92–2.11)

0.113

1.31 (0.83–2.05)

0.244

 University or college

1.16 (0.78–1.72)

0.469

1.25 (0.81–1.94)

0.313

 Graduate degree

1.25 (0.83–1.87)

0.292

1.38 (0.88–2.18)

0.164

Student status

 N´Ç

REF

Ìý

REF

Ìý

 Y±ð²õ

0.73 (0.67–0.79)

 &±ô³Ù; 0.001

0.85 (0.75–0.95)

0.006

Monthly income (CNY)

 &±ô³Ù; 5000

REF

Ìý

REF

Ìý

 5,000–9,999

1.17 (1.06–1.30)

0.002

1.03 (0.90–1.17)

0.699

 10,000–29,999

1.37 (1.16–1.61)

 &±ô³Ù; 0.001

1.29 (1.06–1.56)

0.012

 ≥ 30,000

1.53 (1.11–2.10)

0.009

1.47 (1.04–2.09)

0.028

Cohabitation status

â€Çã±ô´Ç²Ô±ð

REF

Ìý

REF

Ìý

 C´Ç³ó²¹²ú¾±³Ù²¹³Ù¾±´Ç²Ô

0.9 (0.77–1.05)

0.197

1.12 (0.94–1.33)

0.192

Chronic disease

 N´Ç

REF

Ìý

REF

Ìý

 Y±ð²õ

1.21 (1.06–1.39)

0.006

1.05 (0.90–1.22)

0.572

Covid-19 infection status

 U²Ô¾±²Ô´Ú±ð³¦³Ù±ð»å

REF

Ìý

REF

Ìý

 During infection

1.81 (1.46–2.24)

 &±ô³Ù; 0.001

1.47 (1.16–1.85)

0.001

 R±ð³¦´Ç±¹±ð°ù±ð»å

1.22 (1.09–1.37)

0.001

1.17 (1.03–1.33)

0.013

Depressive symptoms

 M¾±²Ô¾±³¾²¹±ô

REF

Ìý

REF

Ìý

 M¾±±ô»å

1.46 (1.33–1.60)

 &±ô³Ù; 0.001

1.14 (1.02–1.27)

0.024

 M´Ç»å±ð°ù²¹³Ù±ð

1.93 (1.70–2.19)

 &±ô³Ù; 0.001

1.34 (1.14–1.57)

 &±ô³Ù; 0.001

â€Çȱ𱹱ð°ù±ð

2.36 (2.08–2.69)

 &±ô³Ù; 0.001

1.38 (1.11–1.70)

0.003

Anxiety symptoms

 M¾±²Ô¾±³¾²¹±ô

REF

Ìý

REF

Ìý

 M¾±±ô»å

1.56 (1.42–1.71)

 &±ô³Ù; 0.001

0.99 (0.88–1.12)

0.865

 M´Ç»å±ð°ù²¹³Ù±ð

1.99 (1.73–2.28)

 &±ô³Ù; 0.001

0.99 (0.81–1.21)

0.953

â€Çȱ𱹱ð°ù±ð

1.94 (1.60–2.35)

 &±ô³Ù; 0.001

1.01 (0.77–1.33)

0.952

PTSD symptoms

 N´Ç

REF

Ìý

REF

Ìý

 Y±ð²õ

1.56 (1.44–1.69)

 &±ô³Ù; 0.001

1.16 (1.05–1.29)

0.003

Have received other vaccines in the past five years

 N´Ç

REF

Ìý

REF

Ìý

 Y±ð²õ

0.96 (0.88–1.06)

0.413

0.97 (0.88–1.07)

0.575

Have experienced adverse reactions after COVID-19 vaccination

 N´Ç

REF

Ìý

REF

Ìý

 Y±ð²õ

1.61 (1.47–1.75)

 &±ô³Ù; 0.001

1.49 (1.36–1.63)

 &±ô³Ù; 0.001

Social Support, mean ± SD

0.87 (0.86–0.87)

 &±ô³Ù; 0.001

0.87 (0.86–0.88)

 &±ô³Ù; 0.001